AC Immune SA (NASDAQ: ACIU) has announced that the second Phase 3 (CREAD 2) clinical trial of crenezumab, AC Immune’s anti-Abeta antibody candidate for treatment...
The post Healthcare Stock to watch: AC Immune SA (NASDAQ: ACIU) appeared first on FXDailyReport.Com.
This post first appeared on FXDailyReport.com - Forex Stock Market News And Analysis, please read the originial post: here
